Molecular Neurodegeneration
Volume 2
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
  CommentaryFrom a Parkinson's disease expert: Rasagiline and the Future of TherapyShaheen E Lakhan  Global Neuroscience Initiative Foundation, Los Angeles, CA, USA  author email corresponding author email
Molecular Neurodegeneration 2007,
2:13doi:10.1186/1750-1326-2-13 Abstract
John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion – Israel Institute of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim were instrumental in the early clinical development of the anti-Parkinson drug rasagiline, which gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006. In our interview, Finberg reflects on his clinical research to develop rasagiline as a commercial drug and its proposed pharmacological mechanisms of action. Moreover, he elucidates the current state of anti-Parkinson drug discovery and offers direction for future research. | 
on Google Scholar
